Volume 23, Issue 1 pp. 67-72

Compatibility and stability of fentanyl admixtures in polypropylene syringes

G. M. Peterson

G. M. Peterson

Tasmanian School of Pharmacy, University of Tasmania, Hobart, Tasmania, Australia

Search for more papers by this author
K. A. Miller

K. A. Miller

Tasmanian School of Pharmacy, University of Tasmania, Hobart, Tasmania, Australia

Search for more papers by this author
J. G. Galloway

J. G. Galloway

Pharmacy Department, Royal Hobart Hospital, Hobart, Tasmania, Australia

Search for more papers by this author
P. F. Dunne

P. F. Dunne

Palliative Care Unit, Repatriation General Hospital, Hobart, Tasmania, Australia

Search for more papers by this author
First published: 09 October 2008
Citations: 13
Gregory M.Peterson Tasmanian School of Pharmacy, Faculty of Health Science, University of Tasmania, GPO Box 252-26, Hobart, Tasmania 7001, Australia.

Abstract

Objective: To determine the physicochemical stability of fentanyl in combination with midazolam and either hyoscine butylbromide or metoclo- pramide, and stored in 30 ml polypropylene syringes. Methods: Solutions containing approximately 40 μg/ml of fentanyl in combination with midazolam (approximately 600 μg/ml) and either metoclopramide (approximately 700 μg/l) or hyoscine (approximately 850 μg/ml) were prepared from commercial ampoules of the drugs. The solutions were stored, in triplicate, in the dark at 32 °C (to simulate usage conditions) for 10 days, and the concentration of each constituent drug was periodically determined using a stability-indicating high-performance liquid chromatography assay. Results: The combinations were relatively stable, with all drugs maintaining over 90% of their initial chemical potency for at least 1 week. There were no evident changes in either the physical appearance or pH values of the solutions over the course of the study. Conclusions: On the basis of physicochemical stability, polypropylene syringes containing fentanyl with midazolam and either hyoscine butylbromide or metoclopramide can be safely prepared and stored at or below 32 °C for periods of up to 1 week prior to use by palliative care patients receiving the drugs via a portable subcutaneous infusion device.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.